Skip to main content

Phase 1 vs Phase 2 — Dermatology Deal Valuation Comparison

Phase 1 Median Upfront
$104M
Total: $927M
Phase 2 Median Upfront
$393M
Total: $2.1B
Stage Premium
129%
Phase 2 premium over Phase 1
Phase 1 Royalties
4.4%-9.8%
vs Phase 2: 6.5%-13.1%

Market Analysis

The Phase 1 to Phase 2 transition in dermatology represents a significant value inflection point. Phase 2 deals carry a median total deal value of $2.1B compared to $927M at Phase 1, a 129% premium reflecting clinical de-risking. Upfront payments increase from $104M to $393M.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the deal value premium from Phase 1 to Phase 2 in dermatology?
Phase 2 dermatology deals command a 129% premium over Phase 1 in total deal value ($2.1B vs $927M). Upfronts increase from $104M to $393M, reflecting the de-risking value of clinical progression.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating